1013 / 1851
RADITUX trial: final results
Overall Survival
Median OS
33 (arm A) vs 30 (arm B) months
p-value 0.722
OS
was remarkably
high
(37% @ 5 years)
Hypofractionated RT +
daily
might contribute to
increase OS
in locally
advanced NSCLC
No positive
results for
Cetuximab and RT
in
stage III NSCLC so far
Walraven I. et al. Radiot Oncol 2016;116